Associate
Antoinette has extensive experience developing global prosecution strategies and managing domestic and international portfolios. She leverages her technical experience in drafting patent applications directed to small molecules, solid forms, pharmaceutical formulations, dosing regimens, and synthetic processes. Her prosecution practice before the U.S. Patent and Trademark Office (USPTO) includes Track One and reissue applications.
Antoinette manages patent portfolios encompassing clinical candidates and combination drug products approved by regulatory agencies worldwide, such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), Health Canada, and the Israel Ministry of Health. She has developed strategies for patent term extension applications as well as supplementary protection certificates for many countries, including the U.K., Australia, Canada, Israel, and Russia. Antoinette provides strategic guidance on patent linkage systems for the U.S. (FDA Orange Book), Canada (Patent Register), Eurasia (Pharmaceutical Register), and other countries. She has expanded her practice to include developing opposition strategies for both pre-grant challenges, specifically in Argentina, Brazil, India, and Uruguay, and post-grant challenges within Europe, Eurasia, Russia, and Uruguay.
Antoinette's experience in organic chemistry spans the areas of natural product synthesis, methodology in synthetic organic chemistry, medicinal chemistry, and chemical biology. Her postdoctoral research included synthesizing anticancer and antimalarial small molecules as well as developing new reaction methodologies for the spirocyclization of (ox)indole bisnucleophiles and for the homologation of masked acyl cyanides. She has also explored the synthesis of anti-prostate cancer flavanoids.
Event
Introduction to Patents and Patent Law Introduction to Patents and Patent Law
February 7, 2024
Virtual
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.